

- Federal Claims No: 19–1639V
89. Denise Bengston, Wichita, Kansas, Court of Federal Claims No: 19–1643V
 90. Shannon Cobb, Blue Springs, Missouri, Court of Federal Claims No: 19–1645V
 91. Robert Labianco, Virginia Beach, Virginia, Court of Federal Claims No: 19–1646V
 92. Tara Hunley, Madera, California, Court of Federal Claims No: 19–1647V
 93. Jessica Sandner, Portland, Oregon, Court of Federal Claims No: 19–1648V
 94. Teresa Buchanan, Chattanooga, Tennessee, Court of Federal Claims No: 19–1649V
 95. Lisa C. Salzer, Salisbury, North Carolina, Court of Federal Claims No: 19–1650V
 96. Robert R. Jodoin, Manchester, New Hampshire, Court of Federal Claims No: 19–1651V
 97. Janice Byrd, Boston, Massachusetts, Court of Federal Claims No: 19–1655V
 98. Janna Glassberg, Boston, Massachusetts, Court of Federal Claims No: 19–1656V
 99. Charisse Guasto, Tomah, Wisconsin, Court of Federal Claims No: 19–1658V
 100. Jordan Briggs, Richardson, Texas, Court of Federal Claims No: 19–1659V
 101. Robert Mele, Washington, Pennsylvania, Court of Federal Claims No: 19–1660V
 102. Kimberly Martin, Dallas, Texas, Court of Federal Claims No: 19–1661V
 103. Richard Rebeles, Chicago, Illinois, Court of Federal Claims No: 19–1662V
 104. Casey Wilson on behalf of C. W., Reno, Nevada, Court of Federal Claims No: 19–1663V
 105. Kevin Carasiti, Wading River, New York, Court of Federal Claims No: 19–1664V
 106. Jennifer Cortez, San Diego, California, Court of Federal Claims No: 19–1669V
 107. Ashley Wirges, Washington, District of Columbia, Court of Federal Claims No: 19–1670V
 108. Valerie K. Hester on behalf of The Estate of Marion Hester, Deceased, Durham, North Carolina, Court of Federal Claims No: 19–1671V
 109. Susan Fitzgerald, Washington, District of Columbia, Court of Federal Claims No: 19–1673V
 110. David Griswold, Mission Hills, California, Court of Federal Claims No: 19–1674V
 111. George Girard Hammer, Jeffersonton, Kentucky, Court of Federal Claims No: 19–1675V
 112. Gerald Lengkeek, Holland, Michigan, Court of Federal Claims No: 19–1678V
 113. Traci Jones, Redlands, California, Court of Federal Claims No: 19–1680V
 114. MaryGrace Fagen, Schererville, Indiana, Court of Federal Claims No: 19–1681V
 115. Kim Reed, Winfield, Alabama, Court of Federal Claims No: 19–1682V
 116. Hanna Reynolds, Davie, Florida, Court of Federal Claims No: 19–1683V
 117. Frank Coluccio, Beverly Hills, California, Court of Federal Claims No: 19–1684V
 118. Sharon Stephens, Victorville, California, Court of Federal Claims No: 19–1685V
 119. Trevor Miller, Allentown, Pennsylvania, Court of Federal Claims No: 19–1686V
 120. Lindsay Carlson, Modena, New York, Court of Federal Claims No: 19–1687V
 121. Kristin Ivanovski, Hackensack, New

- Jersey, Court of Federal Claims No: 19–1690V
122. Emily Hirst, Gainesville, Georgia, Court of Federal Claims No: 19–1691V
 123. Kristi Napier, New Albany, Indiana, Court of Federal Claims No: 19–1692V
 124. Raven Tubbs, Dallas, Texas, Court of Federal Claims No: 19–1693V
 125. Jennifer Kohlmeyer, Englewood, New Jersey, Court of Federal Claims No: 19–1694V
 126. Kathy J. Stopar, Racine, Wisconsin, Court of Federal Claims No: 19–1695V
 127. Nidal Zaidan, Dresher, Pennsylvania, Court of Federal Claims No: 19–1697V
 128. Lindsay Ward, Dresher, Pennsylvania, Court of Federal Claims No: 19–1698V
 129. Mir Hassan, Bloomingdale, Illinois, Court of Federal Claims No: 19–1699V

[FR Doc. 2019–25099 Filed 11–19–19; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HIV/AIDS Clinical Trials Networks Statistical and Data Management Centers (UM1 Clinical Trial Required).

Date: December 12–13, 2019.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Cambria Hotel Rockville, 1 Helen Heneghan Way, Rockville, MD 20850.

Contact Person: Cynthia Louise De La Fuente, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 240–669–2740, delafuentecl@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 14, 2019.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–25116 Filed 11–19–19; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required).

Date: December 16, 2019.

Time: 9:00 a.m. to 11:00 a.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Kelly Lorraine Hudspeth, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC–9823 Rockville, MD 20852, 240–669–5067, kelly.hudspeth@nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Collaborative Cross Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21).

Date: January 8–9, 2020.

Time: 9:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Margaret Allison Morris Fears, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, maggie.morrisfears@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 14, 2019.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–25115 Filed 11–19–19; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HIV/AIDS Adult Therapeutics Clinical Trials Network Leadership and Operations Center (UM1 Clinical Trial Required).

Date: December 6, 2019.

Time: 11:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: J. Bruce Sundstrom, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 5601 Fishers Lane, Room 3G11A, MSC 9823, Bethesda, MD 20892–9823, 240–669–5045, sundstromj@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 14, 2019.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–25112 Filed 11–19–19; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; 60-Day Comment Request; National Institute of Neurological Disorders and Stroke FITBIR Data Access Request

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995, to provide opportunity for public comment on proposed data collection projects, the National Institute of Neurological Disorders and Stroke (NINDS), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

DATES: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Dr. Sophia Jeon, Health Science Policy Analyst, Office of Science Policy and Planning, OSPP, NINDS, NIH, 31 Center Drive, Building 31, Room 8A03, Bethesda, MD 20892, or call non-toll-free number (301) 435–7571, or Email your request, including your address to: sophia.jeon@nih.gov Formal requests for additional plans and instruments must be requested in writing.

SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have

practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Proposed Collection Title: National Institute of Neurological Disorders and Stroke FITBIR Data Access Request, 0925–0677, REINSTATEMENT with change–, Expiration Date 12/31/2019 National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH).

Need and Use of Information Collection: The FITBIR Informatics System Data Access Request form is necessary for Principal Investigators (PIs) and their organization or corporations with approved assurance from the DHHS Office of Human Research Protections to access data or images from the FITBIR Informatics System for research purposes. The primary use of this information is to document, track, monitor, and evaluate the use of the FITBIR datasets, as well as to notify interested recipients of updates, corrections or other changes to the database. For reinstatement of this collection, the agency proposes to add Data Submission Request to allow “Submitter” Principal Investigators (PIs) to request submission of their data to the FITBIR database for broad data sharing and to document, monitor, and track the FITBIR data submissions. Types of respondents affected by this information collection are researchers, such as “Recipient” PIs who are interested in obtaining access to study data and images from the FITBIR Informatics System for research purposes, or “Submitter” PIs who are interested in submitting data to contribute to the FITBIR database for their data to be shared with the traumatic brain injury research community.

OMB approval reinstatement is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 96.